FI104363B - Immunosuppressanttien ja interferonien farmakologisten keskinäisten vaikutusten parantaminen lisäaineilla - Google Patents

Immunosuppressanttien ja interferonien farmakologisten keskinäisten vaikutusten parantaminen lisäaineilla Download PDF

Info

Publication number: FI104363B
Authority: FI; Finland
Prior art keywords: cyclosporins; interferons; rapamycin; peptides; amino acid
Prior art date: 1997-05-19

Application number

FI972121A

Other languages

English (en)

Finnish (fi)

Swedish (sv)

Other versions

FI972121A0 (fi

FI972121L (fi

Inventor

Timo Kalevi Korpela

Vladimir Petrovich Zavialov

Raisa Nikolaevna Vasilenko

Dmitry Aleksandrovich Dolgikh

Mikhail Petrovich Kirpichnikov

Elena Vitalievna Navolotskaya

Original Assignee

Timo Kalevi Korpela

Vladimir Petrovich Zavialov

Raisa Nikolaevna Vasilenko

Dmitry Aleksandrovich Dolgikh

Mikhail Petrovich Kirpichnikov

Elena Vitalievna Navolotskaya

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-05-19

Filing date

1997-05-19

Publication date

2000-01-14

1997-05-19 Application filed by Timo Kalevi Korpela, Vladimir Petrovich Zavialov, Raisa Nikolaevna Vasilenko, Dmitry Aleksandrovich Dolgikh, Mikhail Petrovich Kirpichnikov, Elena Vitalievna Navolotskaya filed Critical Timo Kalevi Korpela

1997-05-19 Priority to FI972121A priority Critical patent/FI104363B/fi

1997-05-19 Publication of FI972121A0 publication Critical patent/FI972121A0/fi

1998-05-18 Priority to EP98921528A priority patent/EP0981359B1/de

1998-05-18 Priority to JP55000998A priority patent/JP2001526675A/ja

1998-05-18 Priority to AU74352/98A priority patent/AU7435298A/en

1998-05-18 Priority to AT98921528T priority patent/ATE234624T1/de

1998-05-18 Priority to PCT/FI1998/000418 priority patent/WO1998052594A1/en

1998-05-18 Priority to DE69812347T priority patent/DE69812347T9/de

1998-11-20 Publication of FI972121L publication Critical patent/FI972121L/fi

2000-01-14 Application granted granted Critical

2000-01-14 Publication of FI104363B publication Critical patent/FI104363B/fi

Links

102000014150 Interferons Human genes 0.000 title claims description 21
108010050904 Interferons Proteins 0.000 title claims description 21
239000003018 immunosuppressive agent Substances 0.000 title abstract description 14
229960003444 immunosuppressant agent Drugs 0.000 title abstract description 12
229940079322 interferon Drugs 0.000 title description 5
239000000654 additive Substances 0.000 title description 3
230000006872 improvement Effects 0.000 title description 3
230000000996 additive effect Effects 0.000 title description 2
230000000144 pharmacologic effect Effects 0.000 title description 2
229930182912 cyclosporin Natural products 0.000 claims abstract description 55
108010036941 Cyclosporins Proteins 0.000 claims abstract description 43
230000000694 effects Effects 0.000 claims abstract description 34
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 27
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims abstract description 23
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims abstract description 23
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims abstract description 23
229960002930 sirolimus Drugs 0.000 claims abstract description 23
QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims abstract description 23
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 22
239000000203 mixture Substances 0.000 claims abstract description 9
102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 8
108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 7
201000010099 disease Diseases 0.000 claims abstract description 4
210000000056 organ Anatomy 0.000 claims abstract description 3
238000002054 transplantation Methods 0.000 claims abstract 2
229940047124 interferons Drugs 0.000 claims description 16
239000003814 drug Substances 0.000 claims description 14
229940079593 drug Drugs 0.000 claims description 13
125000000539 amino acid group Chemical group 0.000 claims description 6
150000001413 amino acids Chemical class 0.000 claims description 4
206010028980 Neoplasm Diseases 0.000 claims description 3
230000000975 bioactive effect Effects 0.000 claims description 3
206010046851 Uveitis Diseases 0.000 claims description 2
201000011510 cancer Diseases 0.000 claims description 2
238000011287 therapeutic dose Methods 0.000 claims description 2
229920001184 polypeptide Polymers 0.000 claims 2
HSFWRNGVRCDJHI-UHFFFAOYSA-N Acetylene Chemical group C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 1
206010025323 Lymphomas Diseases 0.000 claims 1
206010035226 Plasma cell myeloma Diseases 0.000 claims 1
201000004681 Psoriasis Diseases 0.000 claims 1
208000009956 adenocarcinoma Diseases 0.000 claims 1
230000001363 autoimmune Effects 0.000 claims 1
208000037979 autoimmune inflammatory disease Diseases 0.000 claims 1
208000037976 chronic inflammation Diseases 0.000 claims 1
208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
230000003463 hyperproliferative effect Effects 0.000 claims 1
208000032839 leukemia Diseases 0.000 claims 1
206010025135 lupus erythematosus Diseases 0.000 claims 1
206010028417 myasthenia gravis Diseases 0.000 claims 1
201000000050 myeloid neoplasm Diseases 0.000 claims 1
230000004962 physiological condition Effects 0.000 claims 1
230000001105 regulatory effect Effects 0.000 claims 1
206010039073 rheumatoid arthritis Diseases 0.000 claims 1
230000000391 smoking effect Effects 0.000 claims 1
230000002244 anti-lymphoproliferative effect Effects 0.000 abstract description 10
230000027455 binding Effects 0.000 abstract description 9
230000001506 immunosuppresive effect Effects 0.000 abstract description 5
230000001225 therapeutic effect Effects 0.000 abstract description 2
125000003275 alpha amino acid group Chemical group 0.000 abstract 1
230000003321 amplification Effects 0.000 abstract 1
238000003199 nucleic acid amplification method Methods 0.000 abstract 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 33
108010036949 Cyclosporine Proteins 0.000 description 33
229960001265 ciclosporin Drugs 0.000 description 32
229930105110 Cyclosporin A Natural products 0.000 description 31
210000004027 cell Anatomy 0.000 description 28
230000002519 immonomodulatory effect Effects 0.000 description 13
108010014726 Interferon Type I Proteins 0.000 description 12
102000002227 Interferon Type I Human genes 0.000 description 12
230000001589 lymphoproliferative effect Effects 0.000 description 12
230000004044 response Effects 0.000 description 12
101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 11
230000001028 anti-proliverative effect Effects 0.000 description 11
108090000623 proteins and genes Proteins 0.000 description 11
102000004169 proteins and genes Human genes 0.000 description 11
230000035755 proliferation Effects 0.000 description 10
230000002093 peripheral effect Effects 0.000 description 9
230000001965 increasing effect Effects 0.000 description 8
238000000034 method Methods 0.000 description 7
108010086408 albebetin Proteins 0.000 description 6
102000005962 receptors Human genes 0.000 description 6
108020003175 receptors Proteins 0.000 description 6
238000012360 testing method Methods 0.000 description 6
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
230000000638 stimulation Effects 0.000 description 5
210000001744 T-lymphocyte Anatomy 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
231100000135 cytotoxicity Toxicity 0.000 description 4
230000003013 cytotoxicity Effects 0.000 description 4
239000012634 fragment Substances 0.000 description 4
239000001963 growth medium Substances 0.000 description 4
230000002297 mitogenic effect Effects 0.000 description 4
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
230000009885 systemic effect Effects 0.000 description 4
102000004127 Cytokines Human genes 0.000 description 3
108090000695 Cytokines Proteins 0.000 description 3
108010047761 Interferon-alpha Proteins 0.000 description 3
102000006992 Interferon-alpha Human genes 0.000 description 3
102100034404 Nuclear factor of activated T-cells, cytoplasmic 1 Human genes 0.000 description 3
101710151542 Nuclear factor of activated T-cells, cytoplasmic 1 Proteins 0.000 description 3
230000000735 allogeneic effect Effects 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
230000014509 gene expression Effects 0.000 description 3
208000017830 lymphoblastoma Diseases 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
239000002609 medium Substances 0.000 description 3
OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
102000000584 Calmodulin Human genes 0.000 description 2
108010041952 Calmodulin Proteins 0.000 description 2
102000001493 Cyclophilins Human genes 0.000 description 2
108010068682 Cyclophilins Proteins 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
102000000521 Immunophilins Human genes 0.000 description 2
108010016648 Immunophilins Proteins 0.000 description 2
102000000588 Interleukin-2 Human genes 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
108090001090 Lectins Proteins 0.000 description 2
102000004856 Lectins Human genes 0.000 description 2
108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
102000005431 Molecular Chaperones Human genes 0.000 description 2
108010006519 Molecular Chaperones Proteins 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
102000009658 Peptidylprolyl Isomerase Human genes 0.000 description 2
108010020062 Peptidylprolyl Isomerase Proteins 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 2
230000009471 action Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
239000000427 antigen Substances 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
230000001605 fetal effect Effects 0.000 description 2
238000009472 formulation Methods 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
210000002443 helper t lymphocyte Anatomy 0.000 description 2
230000009610 hypersensitivity Effects 0.000 description 2
239000002955 immunomodulating agent Substances 0.000 description 2
229940121354 immunomodulator Drugs 0.000 description 2
230000001861 immunosuppressant effect Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
239000002523 lectin Substances 0.000 description 2
231100001231 less toxic Toxicity 0.000 description 2
239000003226 mitogen Substances 0.000 description 2
229940126701 oral medication Drugs 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
231100000572 poisoning Toxicity 0.000 description 2
230000000607 poisoning effect Effects 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
239000000243 solution Substances 0.000 description 2
241000894007 species Species 0.000 description 2
229960005322 streptomycin Drugs 0.000 description 2
239000000758 substrate Substances 0.000 description 2
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
210000002925 A-like Anatomy 0.000 description 1
208000031295 Animal disease Diseases 0.000 description 1
102000004631 Calcineurin Human genes 0.000 description 1
108010042955 Calcineurin Proteins 0.000 description 1
208000002691 Choroiditis Diseases 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108091011114 FK506 binding proteins Proteins 0.000 description 1
102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000878213 Homo sapiens Inactive peptidyl-prolyl cis-trans isomerase FKBP6 Proteins 0.000 description 1
102100036984 Inactive peptidyl-prolyl cis-trans isomerase FKBP6 Human genes 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
108010085220 Multiprotein Complexes Proteins 0.000 description 1
102000007474 Multiprotein Complexes Human genes 0.000 description 1
241001529936 Murinae Species 0.000 description 1
108010018525 NFATC Transcription Factors Proteins 0.000 description 1
102000002673 NFATC Transcription Factors Human genes 0.000 description 1
102100034400 Nuclear factor of activated T-cells, cytoplasmic 2 Human genes 0.000 description 1
101710151538 Nuclear factor of activated T-cells, cytoplasmic 2 Proteins 0.000 description 1
208000022873 Ocular disease Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
108010089430 Phosphoproteins Proteins 0.000 description 1
102000007982 Phosphoproteins Human genes 0.000 description 1
208000003971 Posterior uveitis Diseases 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 1
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
108010046075 Thymosin Proteins 0.000 description 1
102000007501 Thymosin Human genes 0.000 description 1
241001149964 Tolypocladium Species 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
241000209140 Triticum Species 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
238000006534 Zavyalov synthesis reaction Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
229940125687 antiparasitic agent Drugs 0.000 description 1
239000003096 antiparasitic agent Substances 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000009704 beneficial physiological effect Effects 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
239000012867 bioactive agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
235000008429 bread Nutrition 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000015861 cell surface binding Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
230000030609 dephosphorylation Effects 0.000 description 1
238000006209 dephosphorylation reaction Methods 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
206010014801 endophthalmitis Diseases 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
208000030533 eye disease Diseases 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
210000000744 eyelid Anatomy 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000006870 function Effects 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
239000000185 hemagglutinin Substances 0.000 description 1
231100000304 hepatotoxicity Toxicity 0.000 description 1
230000028993 immune response Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
229940124622 immune-modulator drug Drugs 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
229940124589 immunosuppressive drug Drugs 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000001524 infective effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000031891 intestinal absorption Effects 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000007056 liver toxicity Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000011707 mineral Substances 0.000 description 1
238000000302 molecular modelling Methods 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
230000006213 negative regulation of lymphocyte proliferation Effects 0.000 description 1
231100000417 nephrotoxicity Toxicity 0.000 description 1
230000005937 nuclear translocation Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
229940023490 ophthalmic product Drugs 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
230000002688 persistence Effects 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
238000011555 rabbit model Methods 0.000 description 1
230000005258 radioactive decay Effects 0.000 description 1
210000003370 receptor cell Anatomy 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000003014 reinforcing effect Effects 0.000 description 1
230000008085 renal dysfunction Effects 0.000 description 1
230000006965 reversible inhibition Effects 0.000 description 1
229940063122 sandimmune Drugs 0.000 description 1
230000001932 seasonal effect Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
239000000724 thymus hormone Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
231100000816 toxic dose Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000005945 translocation Effects 0.000 description 1
230000032895 transmembrane transport Effects 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
208000029257 vision disease Diseases 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Transplantation (AREA)
Zoology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

FI972121A 1997-05-19 1997-05-19 Immunosuppressanttien ja interferonien farmakologisten keskinäisten vaikutusten parantaminen lisäaineilla FI104363B (fi)

Priority Applications (7)

Application Number	Priority Date	Filing Date	Title
FI972121A FI104363B (fi)	1997-05-19	1997-05-19	Immunosuppressanttien ja interferonien farmakologisten keskinäisten vaikutusten parantaminen lisäaineilla
EP98921528A EP0981359B1 (de)	1997-05-19	1998-05-18	Zusammensetzungen zur verstärkung der pharmakologischen aktivität von immunosuppressiva
JP55000998A JP2001526675A (ja)	1997-05-19	1998-05-18	免疫抑制剤の薬剤活性を向上させる組成物
AU74352/98A AU7435298A (en)	1997-05-19	1998-05-18	Compositions for enhancing immunosuppressants' pharmaceutical acti vities
AT98921528T ATE234624T1 (de)	1997-05-19	1998-05-18	Zusammensetzungen zur verstärkung der pharmakologischen aktivität von immunosuppressiva
PCT/FI1998/000418 WO1998052594A1 (en)	1997-05-19	1998-05-18	Compositions for enhancing immunosuppressants' pharmaceutical activities
DE69812347T DE69812347T9 (de)	1997-05-19	1998-05-18	Zusammensetzungen zur verstärkung der pharmakologischen aktivität von immunosuppressiva

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FI972121A FI104363B (fi)	1997-05-19	1997-05-19	Immunosuppressanttien ja interferonien farmakologisten keskinäisten vaikutusten parantaminen lisäaineilla
FI972121		1997-05-19

Publications (3)

Publication Number	Publication Date
FI972121A0 FI972121A0 (fi)	1997-05-19
FI972121L FI972121L (fi)	1998-11-20
FI104363B true FI104363B (fi)	2000-01-14

Family

ID=8548873

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI972121A FI104363B (fi)	1997-05-19	1997-05-19	Immunosuppressanttien ja interferonien farmakologisten keskinäisten vaikutusten parantaminen lisäaineilla

Country Status (7)

Country	Link
EP (1)	EP0981359B1 (de)
JP (1)	JP2001526675A (de)
AT (1)	ATE234624T1 (de)
AU (1)	AU7435298A (de)
DE (1)	DE69812347T9 (de)
FI (1)	FI104363B (de)
WO (1)	WO1998052594A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI20021774A7 (fi) *	2002-10-07	2004-04-08	Dmitry Aleksandrovich Dolgikh	Peptidit ja yhdistelmäproteiinit, jotka jäljittelevät interferonien antiviraalia ja kasvua estävää toimintaa
TW200509958A (en) *	2003-02-14	2005-03-16	Combinatorx Inc	Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1990009806A2 (en) *	1989-03-02	1990-09-07	University Of Florida	Composition for the inhibition of tumors and for the non-cytotoxic inhibition of replication of viruses
TW391983B (en) *	1992-10-30	2000-06-01	Univ Florida	Human interferon TAU, processes thereof and pharmaceutical uses thereof
FR2706772A1 (en) *	1993-06-22	1994-12-30	Vacsyn Sa	Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin.

1997
- 1997-05-19 FI FI972121A patent/FI104363B/fi not_active IP Right Cessation
1998
- 1998-05-18 EP EP98921528A patent/EP0981359B1/de not_active Expired - Lifetime
- 1998-05-18 DE DE69812347T patent/DE69812347T9/de not_active Expired - Fee Related
- 1998-05-18 AT AT98921528T patent/ATE234624T1/de not_active IP Right Cessation
- 1998-05-18 JP JP55000998A patent/JP2001526675A/ja not_active Ceased
- 1998-05-18 AU AU74352/98A patent/AU7435298A/en not_active Abandoned
- 1998-05-18 WO PCT/FI1998/000418 patent/WO1998052594A1/en not_active Ceased

Also Published As

Publication number	Publication date
ATE234624T1 (de)	2003-04-15
WO1998052594A1 (en)	1998-11-26
FI972121A0 (fi)	1997-05-19
DE69812347D1 (de)	2003-04-24
EP0981359A1 (de)	2000-03-01
FI972121L (fi)	1998-11-20
DE69812347T9 (de)	2004-09-23
EP0981359B1 (de)	2003-03-19
DE69812347T2 (de)	2004-02-19
JP2001526675A (ja)	2001-12-18
AU7435298A (en)	1998-12-11

Legal Events

Date	Code	Title	Description
2005-11-30	MA	Patent expired

Publication	Publication Date	Title
TWI510622B (zh)	2015-12-01	用於治療及／或預防自體免疫疾病及用於調節性ｔ細胞形成之藥劑
Burman et al.	1986	Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon
US5780021A (en)	1998-07-14	Method for treating type 1 diabetes using α-interferon and/or β-i
AU688214B2 (en)	1998-03-05	Method for treatment of autoimmune diseases using interferon-TAU
CZ55194A3 (en)	1994-10-19	Preparation for treating mammals infected by hepatitis c virus
Klosterhalfen et al.	1996	Influence of heat shock protein 70 and metallothionein induction by zinc-bis-(DL-hydrogenaspartate) on the release of inflammatory mediators in a porcine model of recurrent endotoxemia
JP2001511121A (ja)	2001-08-07	コポリマー１の摂取又は吸入を通じての多発性硬化症の治療
FI104363B (fi)	2000-01-14	Immunosuppressanttien ja interferonien farmakologisten keskinäisten vaikutusten parantaminen lisäaineilla
WO1994001125A1 (en)	1994-01-20	Composition and method of treating hepatitis b
CA2185794C (en)	2007-01-30	Agent for relieving side effects caused by immunosuppressants
US20040191217A1 (en)	2004-09-30	Method of treatment using interferon-tau
JPH10167982A (ja)	1998-06-23	劇症肝炎疾患治療剤
US5317012A (en)	1994-05-31	Human growth hormone induced improvement in depressed T4/T8 ratio
US20030186839A1 (en)	2003-10-02	Medicinal compositions
KR20050054119A (ko)	2005-06-10	잔소리졸을 함유하는 면역억제제
AU2004200074C1 (en)	2006-12-14	Agent for relieving side effects caused by immunosuppressants
JPH11507023A (ja)	1999-06-22	血清免疫調節ポリペプチドおよびそれらの使用
JPH07188049A (ja)	1995-07-25	代謝不全肝疾患の患者の治療のための方法および組成物
AU751199B2 (en)	2002-08-08	Composition and method of treating hepatitis B
COOK	1984	The Mechanism of Induction of Interferon Gamma Synthesis by Human Thymocytes
Stebbing	1990	Proteins as Therapeutics: Potential and Problems
Sze	2004	Chemical and biological characterizations of the edible mushroom Volvariella volvacea lectins
KR20000010724A (ko)	2000-02-25	면역억제제로서의 아스피로클로라인 또는 그의 유도체의 용도
JPH115748A (ja)	1999-01-12	冬眠誘導薬
HK1215790B (en)	2018-08-03	A combination of a cxcr4 antagonist and cytarabine for use in treating myeloid leukemia